Allogene Therapeutics ALLO Software and Technology Licenses, Net
Software and Technology Licenses, Net at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's software and technology licenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's software and technology licenses, net?
- Allogene Therapeutics (ALLO) reported software and technology licenses, net of $3.53M in Q1 2026.
- How has Allogene Therapeutics's software and technology licenses, net changed year-over-year?
- Allogene Therapeutics's software and technology licenses, net increased by 85.8% year-over-year, from $1.9M to $3.53M.
- What is the long-term trend for Allogene Therapeutics's software and technology licenses, net?
- Over 5 years (2020 to 2025), Allogene Therapeutics's software and technology licenses, net has grown at a -6.9% compound annual growth rate (CAGR), from $5.17M to $3.62M.